GSK’s Arexvy receives expanded approval in Canada

GSK’s (LSE: GSK) Arexvy (RSV vaccine) has received an expanded approval in Canada to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults aged 50-59 who are at increased risk.

This approval broadens its prior authorization for adults aged 60 and above, and follows similar regulatory approvals in the USA and the EU. GSK has also filed regulatory submissions for Japan and other geographies, with decisions anticipated soon.

The expansion highlights the risks faced by adults with chronic conditions such as chronic obstructive pulmonary disease, asthma, diabetes, and heart failure. In Canada, 98% of adults hospitalized with RSV are found to have at least one preexisting condition.